Buprenorphine
Partial Opioid Agonist — NERVOUS SYSTEM
Also known as: buprenorfine, buprenorphine HCl, buprenorphine hydrochloride, norspan
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Buprenorphine is an ofp drug in the Partial Opioid Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1981. Its mechanism of action is classified as Partial Opioid Agonists. DrugCentral lists 9 molecular targets, including Oprm1, OPRM1 and Oprd1. Recorded indications include Acute postoperative pain, Chronic pain, Chronic Pain with Opioid Tolerance and Opioid dependence.
- Approval status: ofp (first approved 1981 by the FDA).
- Drug class: Partial Opioid Agonist.
- Mechanism of action: Partial Opioid Agonists.
- Molecular targets: Oprm1, OPRM1, Oprd1 and OPRK1 (9 listed in DrugCentral).
- Indications: Acute postoperative pain, Chronic pain, Chronic Pain with Opioid Tolerance, Opioid dependence and Prevention of opioid abuse and others.
- ATC code: N02AE01 (Oripavine derivatives).
- Molecular formula: C29H41NO4; molecular weight 467.65 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (6)
- Acute postoperative pain
- Chronic pain
- Chronic Pain with Opioid Tolerance
- Opioid dependence
- Prevention of opioid abuse
- Severe pain
Off-label uses (1)
- Opioid withdrawal
Contraindications (32)
- Adrenal cortical hypofunction
- Alcohol intoxication
- Alcohol withdrawal delirium
- Asthenia
- Benign intracranial hypertension
- Benign prostatic hyperplasia
- Central nervous system depression
- Chronic disease of respiratory system
- Chronic hepatitis C
- Chronic obstructive lung disease
- Chronic type B viral hepatitis
- Congenital long QT syndrome
- Cor pulmonale
- Decreased respiratory function
- Dependent drug abuse
- Disease of liver
- Disorder of biliary tract
- Drug-induced psychosis
- Hypercapnia
- Hypothyroidism
- Hypoxia
- Injury of head
- Kyphoscoliosis with Respiratory Compromise
- Lesion of brain
- Liver function tests abnormal
- Orthostatic hypotension
- Pain in Opioid Naive Patients
- Paralytic ileus
- Prolonged QT interval
- Respiratory insufficiency
- + 2 more
Mechanism & targets
| Mechanism of action (MoA) | Partial Opioid Agonists |
|---|---|
| Established pharmacologic class | Partial Opioid Agonist |
Molecular targets (9)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Mu-type opioid receptor | Oprm1 | unknown | Ki 9.89 |
| Mu-type opioid receptor | OPRM1 | unknown | Ki 9.40 |
| Delta-type opioid receptor | Oprd1 | unknown | Ki 9.32 |
| Kappa-type opioid receptor | OPRK1 | unknown | Ki 9.30 |
| Kappa-type opioid receptor | OPRK1 | antagonist | Ki 9.01 |
| Mu-type opioid receptor | OPRM1 | partial agonist | Ki 8.29 |
| Delta-type opioid receptor | OPRD1 | antagonist | Ki 8.07 |
| Nociceptin receptor | OPRL1 | unknown | Ki 7.11 |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | IC50 5.10 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-06-19 | EMA | — | L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A. | |
| 1981-12-29 | FDA | — | RECKITT BENCKISER |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N02AE01 | NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Oripavine derivatives |
N07BC01 | NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › DRUGS USED IN ADDICTIVE DISORDERS › Drugs used in opioid dependence |
N07BC51 | NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › DRUGS USED IN ADDICTIVE DISORDERS › Drugs used in opioid dependence |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Drug withdrawal syndrome | 4075.0 |
| Drug abuse | 3550.4 |
| Product adhesion issue | 1993.2 |
| Drug dependence | 1761.6 |
| Application site pruritus | 1758.5 |
| Drug withdrawal syndrome neonatal | 1757.9 |
| Application site erythema | 1232.7 |
| Substance abuse | 1156.7 |
| Application site rash | 1027.9 |
| Drug use disorder | 1020.1 |
| Withdrawal syndrome | 1002.0 |
| Blepharospasm | 937.6 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Buprenorphine is on its molecule page.
| Molecular formula | C29H41NO4 |
|---|---|
| Molecular weight | 467.65 g/mol |
| CAS number | 52485-79-7 |
| InChIKey | RMRJXGBAOAMLHD-IHFGGWKQSA-N |
| PubChem CID | 644073 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Buprenorphine used for?
DrugCentral lists the following indications for Buprenorphine: Acute postoperative pain, Chronic pain, Chronic Pain with Opioid Tolerance, Opioid dependence, Prevention of opioid abuse and Severe pain.
How does Buprenorphine work?
Buprenorphine is classified as Partial Opioid Agonists; its molecular targets in DrugCentral include Oprm1, OPRM1, Oprd1 and OPRK1.
When was Buprenorphine first approved?
Buprenorphine was first approved by the FDA in 1981.
What drug class does Buprenorphine belong to?
Buprenorphine is in the Partial Opioid Agonist class.
What is the chemical formula of Buprenorphine?
Buprenorphine has the molecular formula C29H41NO4 and a molecular weight of 467.65 g/mol.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 434 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2368861 — compound record and bioactivity
- PubChem CID 644073 — chemical identifiers
- DrugBank DB00921 — drug record
- FDA UNII 40D3SCR4GZ — substance identity
- DailyMed: FDA labels for Buprenorphine — current prescribing information (label search)
- UniProt P41145 (OPRK1) — target protein
- UniProt P35372 (OPRM1) — target protein
- UniProt P41143 (OPRD1) — target protein
- UniProt P41146 (OPRL1) — target protein
- UniProt Q12809 (KCNH2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.